General

cfDNA_Discoveries_700x233

How to optimize the preanalytical portion of your circulating cell-free DNA (cfDNA) studies

Advances in liquid biopsy are allowing new strides in studies involving circulating cell-free DNA (cfDNA). With initial use in the prenatal testing field, cfDNA began to tell its story in fetal DNA genetic testing and has offered an alternative to the invasive and risk-prone amniocentesis. Now, it is breaking barriers in the field of cancer… Read article →



CirculatingTumorCells_700x233

HER2-positive circulating tumor cells in primary breast cancer patients with HER2-negative tumors

In metastatic breast cancer patients, the presence of circulating tumor cells (CTCs) in the blood predicts shorter progression-free survival and lower overall survival (1). Persistent CTCs after treatment also predict a lack of therapeutic response (2). Although the prognostic significance of CTCs in metastatic patients is well established, fewer studies have examined CTCs in primary… Read article →



gDNA isolation

What are the top factors in successful gDNA isolation and quality control?

The quality of extracted genomic DNA (gDNA) is a critical factor in numerous downstream applications, such as next-generation sequencing (NGS) and real-time PCR. gDNA isolation from certain sample types can be challenging, though, and getting back to the basics of purification and quality control can help us understand how to best approach these challenges. QIAGEN’s… Read article →